

Raptor Pharmaceutical Corp
Form 4
October 03, 2014

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Hyperion Trading Segregated Portfolio

(Last) (First) (Middle)

C/O TMF LTD. GRAND PAVILLION COMM. CTR, 2ND FL., 802 WEST BAY ROAD, PO BOX 10338

(Street)

GRAND CAYMAN, E9 KY1-1003

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Raptor Pharmaceutical Corp [RPTP]

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2012

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

___ Director ___X___ 10% Owner
___ Officer (give title below) ___ Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
X Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value \$0.001 per share ⁽¹⁾	05/08/2012		P		11,700	A	\$ 5.56 ⁽²⁾
Common Stock, par value \$0.001 per share ⁽¹⁾	05/09/2012		S		6,500	D	\$ 5.64

Edgar Filing: Raptor Pharmaceutical Corp - Form 4

Common Stock, par value	06/01/2012	P	3,000	A	\$ 5.22	4,893,787	D
\$0.001 per share ⁽¹⁾							
Common Stock, par value	06/04/2012	P	2,000	A	\$ 5.2	4,895,787	D
\$0.001 per share ⁽¹⁾							
Common Stock, par value	06/12/2012	P	8,000	A	\$ 5.35	4,903,787	D
\$0.001 per share ⁽¹⁾							
Common Stock, par value	06/13/2012	S	2,400,000	D	\$ 5.44	2,503,787	D
\$0.001 per share ⁽¹⁾							

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repor Trans (Instr
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address

Relationships

Reporting Owners

Edgar Filing: Raptor Pharmaceutical Corp - Form 4

Director 10% Owner Officer Other

Hyperion Trading Segregated Portfolio
C/O TMF LTD. GRAND PAVILLION COMM. CTR
2ND FL., 802 WEST BAY ROAD, PO BOX 10338
GRAND CAYMAN, E9 KY1-1003

X

Signatures

/s/ David P.M. Blair and Richard A.
Reinert

08/19/2014

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares of common stock, \$0.001 par value per share (the "Common Shares"), of Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), reported herein were held by Hyperion Trading Segregated Portfolio (the "Reporting Person"), a segregated portfolio of Strategic Investment Tribes Fund SPC, a Cayman Islands exempted company registered as a segregated portfolio company, managed by Star Arrow Funds Expertise Ltd, a company organized under the laws of Anguilla ("Star").
- (2) This price represents the weighted average purchase price of the Common Shares on May 8, 2012, which were purchased in multiple transactions ranging from \$5.55 to \$5.56, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the Staff of the Securities and Exchange Commission, upon request, the full information regarding the number of Common Shares bought at each separate price within the ranges set forth in this Form 4.

Remarks:

1. The Common Shares reported herein represent transactions undertaken by the Reporting Person. Pursuant to Reg. Section 2

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.